香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全 部或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （股份代號：1666） 建議續訂持續關連交易 銷售框架性協議及採購框架性協議 董事會謹此宣佈，由於本公司與集團公司訂立之銷售框架性協議及採購框架性協議 均將於二零二五年十二月三十一日到期，故訂約各方於二零二五年九月二十九日續 訂該等協議，協議期限均自二零二六年一月一日起至二零二八年十二月三十一日 止，為期三年，並分別訂立上述協議項下截至二零二八年十二月三十一日止三個年 度之各自擬進行之持續關連交易年度上限。 於本公告日期，集團公司乃本公司之最終控股股東，故根據香港上市規則為本公司 之關連人士。因此，根據香港上市規則第14A章，續訂之銷售框架性協議及續訂之 採購框架性協議項下擬進行之交易均構成本公司之持續關連交易。 由於續訂之銷售框架性協議及續訂之採購框架性協議項下擬進行之持續關連交易預 期年度上限之一項或多項適用百分比率分別均高於5%，因此，續訂之銷售框架性協 議及續訂之採購框架性協議及其項下擬進行之持 ...

Core Viewpoint - Beijing Tongrentang Technology Development Co., Ltd. showcased traditional Chinese medicine at the 2025 China Open Tennis Tournament, blending ancient practices with modern health concepts to attract a younger audience [1][12]. Group 1: Product Showcase - The exhibition featured a variety of traditional Chinese medicine products, including Shengmai Drink, Liuwei Dihuang Wan, and Jingshi Niuhuang Jiedu Pian, highlighting the company's strong foundation in traditional medicine [3]. - A range of health products was also presented, such as health drinks, skincare masks, and hair care products, aligning with the health-oriented philosophy of the event [5]. Group 2: Engagement with Athletes - Notable tennis player Sorana Cirstea participated in a hands-on experience of making herbal sachets, demonstrating the interactive approach of the exhibition [8][10]. - The company aims to enhance global recognition of traditional Chinese medicine through athlete involvement and innovative presentations [12]. Group 3: Scent Products - The company introduced its "Bencao Zhi Yue" series and other aromatic products at the player’s banquet, which became a popular attraction among attendees [13][16]. - The scent products are developed based on the concept of "medicinal fragrance," with nearly 140 products available, focusing on benefits like sleep aid and relaxation [18]. Group 4: Market Expansion - The products were also made available in 16 authorized cultural and creative stores during the event, expanding the reach of Tongrentang's offerings to a broader audience [21].

Core Points - Tong Ren Tang Technologies (01666.HK) announced that its subsidiary, Tong Ren Tang Guo Yao, has received a Traditional Medicine Registration License from the Ministry of Health of the Kingdom of Cambodia, allowing the sale of "Tong Ren Tang An Gong Niu Huang Wan" in Cambodia [1][2] Group 1 - The registered product is "Tong Ren Tang An Gong Niu Huang Wan" [2] - The license holder is Beijing Tong Ren Tang Guo Yao Co., Ltd., located at 14/F, 1405-1409, Convention Plaza, 1 Harbour Road, Wan Chai, Hong Kong [2] - The registration number is CAM N0004IT-25, and the license is valid until September 11, 2028 [2] Group 2 - The acquisition of the license will help enrich the distribution channels of the group's key products and facilitate market expansion [2] - The impact of this license on the group's production operations and performance is not expected to be significant [2] - Sales of the medicine may be influenced by changes in Cambodia's policy environment, exchange rate fluctuations, and market competition [2]

Core Insights - Tong Ren Tang Technology (01666.HK) announced that its subsidiary, Tong Ren Tang Guo Yao, has received a Traditional Medicine Registration License from the Ministry of Health of the Kingdom of Cambodia, allowing the sale of "Tong Ren Tang An Gong Niu Huang Wan" in Cambodia [1][2] Group 1 - The drug "Tong Ren Tang An Gong Niu Huang Wan" is now authorized for sale in Cambodia, which will enhance the distribution channels for the company's key products and support market expansion [1][2] - The registration number for the license is CAM N0004IT-25, and it is valid until September 11, 2028 [2] - The acquisition of this license is not expected to have a significant impact on the company's production operations and performance in the short term [2] Group 2 - The sales of the drug may be influenced by changes in Cambodia's policy environment, exchange rate fluctuations, and market competition [2][3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 自願公告 獲發傳統藥品註冊許可證 1 二、 藥品的其他相關情況 「同仁堂安宮牛黃丸」應遵照持證的中醫師的指導下使用。另外，早前柬埔寨衛生部亦 已頒發「同仁堂安宮牛黃丸」進口許可證。 本公告由北京同仁堂科技發展股份有限公司（「本公司」，連同本公司之附屬公司，「本 集團」）之董事會（「董事會」）自願作出，旨在使本公司股東及潛在投資者了解本集 團之最新業務發展。 董事會欣然宣佈，本公司之附屬公司北京同仁堂國藥有限公司（「同仁堂國藥」）於近 日收到柬埔寨王國（「柬埔寨」）衛生部藥品與食品司頒發的《傳統藥品註冊許可證》 （「許可證」），准許將同仁堂國藥的「同仁堂安宮牛黃丸」在柬埔寨出售，相關情況 公告如下： 一、 藥品基本狀況 藥品名稱：同仁堂安宮牛黃丸 許可證持有人名稱及地址：北京同仁堂國藥有限公司，中國香港灣仔港灣道 1 號會展廣 場辦公大樓 ...

Core Insights - The Chinese health food industry is experiencing a structural transformation characterized by "inventory reshuffling and weakened growth," moving away from the era of broad-based growth due to regulatory upgrades and evolving consumer concepts [2][10] Industry Overview - In the first half of 2025, the online market for health food reached a sales figure of 60.41 billion yuan, with a year-on-year growth rate of 16.2%, indicating the sector's competitive intensity [2] - Major companies are facing declining revenues, with inventory turnover days increasing, signaling a challenging environment for traditional growth models [2][10] Company Performance - The vitality ranking of health food companies shows significant performance disparities, with innovative companies gaining a premium [4][5] - Key players like健合集团 reported a revenue of 7.02 billion yuan, with a 71.7% increase in revenue from emerging Asian markets, highlighting successful global strategies [5] - 仙乐健康, a leading CDMO, achieved a revenue of 2.042 billion yuan (+2.57%), with a remarkable 200% growth in private traffic contributing to its success [7] - 汤臣倍健's second-quarter net profit grew by 71.4%, indicating effective inventory management and operational efficiency [9] Market Trends - The health food sector is witnessing structural growth, with significant differentiation in performance across companies and product categories [5] - Categories such as cardiovascular health (37.4% growth), bone health (34.9% growth), and women's health (26.0% growth) are emerging as key growth drivers [10] - The shift towards new consumption channels, including live streaming and private domains, is becoming crucial for enhancing customer loyalty and combating rising public traffic costs [10][13] Future Outlook - The industry is expected to continue its trend of differentiation, with a focus on precision, technology, and globalization as core competitive strategies [10][12] - Companies are encouraged to explore overseas markets, particularly in Southeast Asia and Latin America, to leverage demographic advantages and growth potential [13] - The competition is entering a new phase centered on quality improvement, with long-term strategic focus and technological accumulation being vital for success [13]

Core Viewpoint - The China Tong Ren Tang Group hosted the third Traditional Chinese Medicine Conference, showcasing its commitment to innovation and high-quality development in traditional Chinese medicine through a comprehensive display of products and research achievements [1] Product Matrix Presentation - Tong Ren Tang Technology Company presented over twenty major products, including Xihuang Pills, Jingzhi Niuhuang Jiedu Tablets, Liuwei Dihuang Pills, and others, covering categories such as anti-cancer, tonics, kidney diseases, and detoxification [3] - The company has developed a "six-dimensional product matrix" around its more than 200 traditional Chinese medicine products, ensuring that each product meets specific consumer needs [5] Rich Product Categories - The diverse range of health products, including Ejiao honey dates, herbal essence masks, and weight loss teas, attracted significant attention from medical professionals and researchers [5] - The company emphasizes the integration of traditional techniques with modern innovation, showcasing its commitment to quality and consumer health [5] Attention to Processing Techniques - The "intangible cultural heritage" exhibition highlighted the company's traditional processing techniques, which enhance the efficacy and adaptability of traditional Chinese medicine [6][8] - The processing methods, such as the treatment of herbs to improve absorption and reduce adverse effects, were demonstrated, showcasing the company's dedication to maintaining the integrity of traditional practices [10] Research and Innovation Driving Development - The company presented solid laboratory data on major products at the conference, enhancing consumer and client understanding of product efficacy [11] - Ongoing research includes clinical studies on various traditional Chinese medicine products, providing a scientific basis for their clinical applications [11]

Core Insights - The article discusses the transformation of mooncakes from traditional sweet treats to health-oriented products, driven by changing consumer preferences among both the Z generation and the elderly population [2][21]. Group 1: Market Trends - The mooncake market is evolving into a 5 billion yuan new segment, influenced by the health consciousness of consumers [2]. - The search volume for "medicinal food mooncakes" surged by 287% year-on-year, with consumers aged 25-35 making up over half of the searches [18]. - The sales of self-use mooncake gift boxes are projected to grow by 81% year-on-year in 2024, with products containing functional ingredients showing the highest repurchase rates [18]. Group 2: Consumer Behavior - The new consumer groups exhibit distinct characteristics, such as a focus on functional ingredients, diverse consumption scenarios, and a strong interest in cultural narratives [23]. - The elderly demographic prioritizes practical benefits, as seen in products like low-sugar buckwheat mooncakes that cater to their dietary needs [25]. Group 3: Supply Chain Innovations - Traditional brands are rapidly adapting to new demands, with companies like Tongrentang extending their pharmaceutical expertise into food products [25]. - Innovations include the use of microencapsulation technology to mask bitter flavors while retaining over 90% of active ingredients [25][34]. Group 4: Industry Dynamics - The mooncake sales landscape is shifting from seasonal sales to year-round availability, with a notable increase in breakfast and afternoon tea consumption scenarios [18][30]. - The integration of technology in production processes has improved the stability and taste of functional mooncakes, enhancing consumer acceptance [34]. Group 5: Cultural Significance - Mooncakes are increasingly viewed as cultural carriers, with products reflecting traditional craftsmanship and health philosophies [39][41]. - The narrative around mooncakes is evolving, emphasizing health and cultural identity, which resonates with modern consumers [41].

中期業績報告 INTERIM REPORT 2025 2025 2025 | 摘要 | | --- | 2 北京同仁堂科技發展股份有限公司 二零二五年中期報告 • 截至二零二五年六月三十日止六個月，本集團銷售收入較二零二四年同期下 降約7.69%。 • 截至二零二五年六月三十日止六個月，歸屬於本公司所有者之利潤較二零 二四年同期下降約21.01%。 • 截至二零二五年六月三十日止六個月，歸屬於本公司所有者之每股收益為人 民幣0.26元。 • 董事會決議不派發截至二零二五年六月三十日止六個月之中期股息。 中期業績（未經審核） 北京同仁堂科技發展股份有限公司（「本公司」或「公司」）之董事會（「董事會」）欣然宣 佈本公司及其子公司（以下合稱「本集團」）截至二零二五年六月三十日止六個月（「報 告期」）未經審核之業績： 簡明合併利潤表（未經審核） | | | 截至六月三十日止六個月 | | | --- | --- | --- | --- | | | | 二零二五年 | 二零二四年 | | | | （未經審核） | （未經審核） | | | 附註 | 人民幣千元 | 人民幣千元 | | 收入 | 6 | 3,738,50 ...

Group 1 - The pharmaceutical sector, particularly the innovative drug segment, has shown strong performance this year, driven by technological innovation and asset revaluation in China [1] - The traditional Chinese medicine (TCM) sector has also performed well but lags behind the innovative drug segment, making it a potential area for investment as market participants seek to "catch up" [1] - Tongrentang Technology, a leading company in the TCM industry, has demonstrated policy certainty, consumer demand, and technological empowerment potential, making it a valuable investment opportunity [1] Group 2 - In the first half of 2025, Tongrentang Technology achieved revenue of 3.74 billion RMB and a net profit of 480 million RMB, showcasing a solid operational performance [2] - The company focuses on optimizing production processes and enhancing quality management to ensure stable product supply and sustainable development [2] - Tongrentang Technology is implementing differentiated marketing strategies for its six major product lines, enhancing market penetration and customer loyalty [2] Group 3 - The company benefits from a unique combination of traditional branding, modern technology, and policy support, which enhances its market recognition and valuation potential [3] - Tongrentang Technology's long history and strong brand presence in the TCM sector provide a stable revenue and profit outlook, making it attractive in the current bull market [4] - The company is investing in smart production and research innovation, significantly improving production efficiency and supporting valuation growth [5] Group 4 - The focus on innovative drug development, particularly in cardiovascular and health supplement areas, is expected to drive future revenue growth for Tongrentang Technology [6] - National policies supporting the TCM industry provide significant development opportunities, enhancing the company's international market presence and brand influence [7] Group 5 - The TCM industry is transitioning from traditional experience-based practices to technology-driven approaches, positioning it for high-quality development [8] - Tongrentang Technology is poised to seize greater development opportunities in this new industry phase, enhancing its market position and capital value [8]